Gland Pharma schedules meeting with institutional investor Panvira

Gland Pharma Limited will hold an analyst/institutional investor meeting on December 16, 2025, with Panvira Investment Management. This one-on-one meeting aims to facilitate dialogue between the company and investors, as per Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company emphasizes that the meeting schedule is subject to change based on exigencies.

The announcement was dispatched to both BSE Limited and the National Stock Exchange of India Limited. For BSE, the communication was sent to the Corporate Relationship Department at Phiroze Jeejeebhoy Towers, Mumbai, with the scrip code 543245. For the NSE, it was directed to the Listing Department at Exchange Plaza, Bandra Kurla Complex, Mumbai, under the symbol GLAND (ISIN: INE068V01023).

The intimation was signed by Sampath Kumar Pallerlamudi, company secretary & compliance officer of Gland Pharma Limited. This proactive disclosure of investor interactions highlights Gland Pharma's commitment to transparency and regular communication with its stakeholders.